6YSY

Skeletal Myosin bound to MPH-220, MgADP-VO4

  • Classification: MOTOR PROTEIN
  • Organism(s): Oryctolagus cuniculus
  • Mutation(s): No 

  • Deposited: 2020-04-23 Released: 2021-03-03 
  • Deposition Author(s): Canon, L., Kikuti, C.M., Gyimesi, M., Malnasi-Csizmadia, A., Houdusse, A.
  • Funding Organization(s): Hungarian National Research, Development and Innovation Office, Hungarian Ministry of Finance, French League Against Cancer, Centre National de la Recherche Scientifique (CNRS), Foundation for Medical Research (France), French National Research Agency, French Muscular Dystrophy Association, Laboratories of Excellence (LabEx)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.25 Å
  • R-Value Free: 0.232 
  • R-Value Work: 0.217 
  • R-Value Observed: 0.218 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Single Residue Variation in Skeletal Muscle Myosin Enables Direct and Selective Drug Targeting for Spasticity and Muscle Stiffness.

Gyimesi, M.Horvath, A.I.Turos, D.Suthar, S.K.Penzes, M.Kurdi, C.Canon, L.Kikuti, C.Ruppel, K.M.Trivedi, D.V.Spudich, J.A.Lorincz, I.Rauscher, A.A.Kovacs, M.Pal, E.Komoly, S.Houdusse, A.Malnasi-Csizmadia, A.

(2020) Cell 183: 335-346.e13

  • DOI: https://doi.org/10.1016/j.cell.2020.08.050
  • Primary Citation of Related Structures:  
    6YSY

  • PubMed Abstract: 

    Muscle spasticity after nervous system injuries and painful low back spasm affect more than 10% of global population. Current medications are of limited efficacy and cause neurological and cardiovascular side effects because they target upstream regulators of muscle contraction. Direct myosin inhibition could provide optimal muscle relaxation; however, targeting skeletal myosin is particularly challenging because of its similarity to the cardiac isoform. We identified a key residue difference between these myosin isoforms, located in the communication center of the functional regions, which allowed us to design a selective inhibitor, MPH-220. Mutagenic analysis and the atomic structure of MPH-220-bound skeletal muscle myosin confirmed the mechanism of specificity. Targeting skeletal muscle myosin by MPH-220 enabled muscle relaxation, in human and model systems, without cardiovascular side effects and improved spastic gait disorders after brain injury in a disease model. MPH-220 provides a potential nervous-system-independent option to treat spasticity and muscle stiffness.


  • Organizational Affiliation

    MTA-ELTE Motor Pharmacology Research Group, Pázmány Péter sétány 1/c, 1117 Budapest, Hungary; Motorpharma, Ltd., Szilágyi Erzsébet fasor 27, 1026 Budapest, Hungary. Electronic address: mate.gyimesi@elte.hu.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Myosin-41,938Oryctolagus cuniculusMutation(s): 0 
UniProt
Find proteins for Q28641 (Oryctolagus cuniculus)
Explore Q28641 
Go to UniProtKB:  Q28641
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ28641
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
Myosin light chain 1/3, skeletal muscle isoform192Oryctolagus cuniculusMutation(s): 0 
UniProt
Find proteins for P02602 (Oryctolagus cuniculus)
Explore P02602 
Go to UniProtKB:  P02602
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP02602
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 4 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
ADP
Query on ADP

Download Ideal Coordinates CCD File 
C [auth A]ADENOSINE-5'-DIPHOSPHATE
C10 H15 N5 O10 P2
XTWYTFMLZFPYCI-KQYNXXCUSA-N
PJT (Subject of Investigation/LOI)
Query on PJT

Download Ideal Coordinates CCD File 
F [auth A](9~{S})-5-methyl-12-(4-morpholin-4-ylphenyl)-9-oxidanyl-4-thia-2,12-diazatricyclo[7.3.0.0^{3,7}]dodeca-1,3(7),5-trien-8-one
C20 H21 N3 O3 S
KUIAFBSRBMWQQP-HXUWFJFHSA-N
VO4
Query on VO4

Download Ideal Coordinates CCD File 
D [auth A]VANADATE ION
O4 V
LSGOVYNHVSXFFJ-UHFFFAOYSA-N
MG
Query on MG

Download Ideal Coordinates CCD File 
E [auth A]MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
Modified Residues  1 Unique
IDChains TypeFormula2D DiagramParent
M3L
Query on M3L
A
L-PEPTIDE LINKINGC9 H21 N2 O2LYS
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.25 Å
  • R-Value Free: 0.232 
  • R-Value Work: 0.217 
  • R-Value Observed: 0.218 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 49.607α = 90
b = 119.424β = 90
c = 176.631γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
autoPROCdata scaling
MOLREPphasing
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Hungarian National Research, Development and Innovation OfficeHungaryNVKP 16-1-2016-0051
Hungarian Ministry of FinanceHungaryGINOP-2.1.7-15-2016-02580
Hungarian Ministry of FinanceHungaryGINOP 2.3.2-15-2016-00016
French League Against CancerFranceIP/SC-16058
Centre National de la Recherche Scientifique (CNRS)France--
Foundation for Medical Research (France)FranceDCM20181039553
French National Research AgencyFranceANR-17-CE11-0029-01
French Muscular Dystrophy AssociationFranceAFM 21805
French National Research AgencyFranceANR-10-IDEX-0001-02-PSL
Laboratories of Excellence (LabEx)France11-LBX-0038

Revision History  (Full details and data files)

  • Version 1.0: 2021-03-03
    Type: Initial release
  • Version 1.1: 2024-01-24
    Changes: Data collection, Database references, Refinement description